Group One Trading Reduces $633K in Abeona Therapeutics Inc. ($ABEO)
Key Points
- Group One Trading changed its Abeona Therapeutics Inc. ($ABEO) stake by 35.3% last quarter, cutting to 209,607 shares worth $1.16 million.
- $ABEO last traded around $5.53.
Group One Trading reduced its position in Abeona Therapeutics Inc. ($ABEO) by 35.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 209,607 shares of Abeona Therapeutics Inc. after selling 114,379 shares during the quarter. Group One Trading's holdings in Abeona Therapeutics Inc. were worth $1.16 million as of its most recent filing.
Abeona Therapeutics Inc. ($ABEO) Stock
Abeona Therapeutics Inc. Earnings
Analysts Set New Price Targets
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.